Table S3. Most popular publication types in all glioblastoma research and in research on identified treatment options in glioblastoma.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Order** | **Publication type** | **Publications on glioblastoma** | **Average citation count per publication per year** | **Publications on identified treatment options** | **Average citation count per publication per year** | **Publications on identified treatment options as percent of all glioblastoma** |
| 1 | Research, funding from non-US government agency | 12655 [39.05%] | 5.97 | 3945 [37.81%] | 6.55 | 31.17% |
| 2 | Research, support from an NIH grant | 3548 [10.95%] | 9.12 | 1129 [10.82%] | 8.86 | 31.82% |
| 3 | Review | 3413 [10.53%] | 5.98 | 1182 [11.33%] | 5.94 | 34.63% |
| 4 | Case Reports | 2351 [7.25%] | 1.12 | 604 [5.79%] | 1.67 | 25.69% |
| 5 | Research, Public Health Service (PHS) support | 1467 [4.53%] | 5.53 | 393 [3.77%] | 7.2 | 26.79% |
| 6 | Comparative Study | 1451 [4.48%] | 4.34 | 469 [4.49%] | 5.33 | 32.32% |
| 7 | Clinical Trial | 737 [2.27%] | 5.38 | 512 [4.91%] | 6.12 | 69.47% |
| 8 | Research, US government agency, non-PHS support | 690 [2.13%] | 7.12 | 204 [1.95%] | 6.74 | 29.57% |
| 9 | English Abstract | 645 [1.99%] | 0.21 | 154 [1.48%] | 0.21 | 23.88% |
| 10 | Clinical Trial, Phase II | 557 [1.72%] | 7.64 | 507 [4.86%] | 7.87 | 91.02% |
| 11 | Comment | 485 [1.50%] | 0.9 | 113 [1.08%] | 1.11 | 23.30% |
| 12 | Multicenter Study | 452 [1.39%] | 12.49 | 323 [3.10%] | 14.74 | 71.46% |
| 13 | Letter | 364 [1.12%] | 1.23 | 83 [0.80%] | 1.65 | 22.80% |
| 14 | Clinical Trial, Phase I | 297 [0.92%] | 7.8 | 263 [2.52%] | 7.51 | 88.55% |
| 15 | Randomized Controlled Trial | 289 [0.89%] | 15.99 | 239 [2.29%] | 18.19 | 82.70% |
| 16 | Evaluation Studies | 256 [0.79%] | 4.76 | 80 [0.77%] | 5.02 | 31.25% |
| 17 | Editorial | 208 [0.64%] | 1.11 | 49 [0.47%] | 1.62 | 23.56% |
| 18 | Research, Intramural Program of NIH support | 155 [0.48%] | 6.94 | 46 [0.44%] | 8.09 | 29.68% |
| 19 | Meta-Analysis | 129 [0.40%] | 5.22 | 55 [0.53%] | 5.96 | 42.64% |
| 20 | Published Erratum | 106 [0.33%] | 0.24 | 19 [0.18%] | 0.02 | 17.92% |
| 21 | Systematic Review | 95 [0.29%] | 5.4 | 47 [0.45%] | 5.06 | 49.47% |
| 22 | Clinical Trial, Phase III | 85 [0.26%] | 35.76 | 79 [0.76%] | 37.05 | 92.94% |
| … | … | … | … | … | … | … |
|  |  | **32,410 [100%]** | **4.27** (average) | **10,435 [100%]** | **4.73** (average) | **32.20%** (average) |